Morrison Foerster is an international law firm with lawyers practicing throughout the United States, Asia, and Europe. Click to discover more.

mofo_share_image.jpg

Morrison Foerster

common-default.jpeg

Terms / Notices

Cookies

Privacy Policy

Reporting Hotline

Attorney Advertising

Alumni

  Linkedin

MoFo LinkedIN

  Facebook

MoFo Facebook

YouTube

MoFo Youtube

Morrison Foerster - Footer

ChinaBio® Partnering Forum 2024: Top Five Risks and Opportunities to Watch in China Life Sciences in the Coming Year

You have not solved the recaptcha challenge yet or session expired, try again.

Email Disclaimer

Disclaimer

Unsolicited e-mails and information sent to Morrison Foerster will not be considered confidential, may be disclosed to others pursuant to our <a href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>, may not receive a response, and do not create an attorney-client relationship with Morrison Foerster. If you are not already a client of Morrison Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

Feedback

mofo-logo-2022.svg

People

Capabilities

Resources

About

Community

Offices

Careers

Stay Connected

In this session, we bring a panel of legal leaders to discuss topics to help life sciences companies navigate risks and identify opportunities. 

<h3>Sorry, we weren’t able to find the terms you entered.</h3>Please try a different term or keyword.

People

Capabilities

Resources

Not Found Cards

In this session, we present a panel to discuss topics that will help life sciences companies navigate risks and identify opportunities. You will hear insights from Morrison Foerster partners: Janet Xiao, an IP expert and head of the firm’s China Life Sciences group; Chuan Sun, who has extensive experience in life sciences M&A and licensing transactions; Rongjing Zhao, who is highly experienced in cross-border M&A transactions; and Chen Zhu, who has extensive experience advising on sanctions and export control issues. The panel will be moderated by MoFo associate Sarah Wang.<ul><li>Through much of 2024, we’ve witnessed the continued trends in cross-border out-licensing deals for Chinese life sciences companies. What are the Dos and Don’ts for companies out‑licensing and acquiring technology generated in China for the overseas market?</li><li>As companies are looking for strategic investments, what are the key considerations to strategically divest non-China assets to an overseas entity to release capital and maximize investment?</li><li>With the promulgation of China’s Personal Information Protection Law, Data Security Law, and the relevant implementation regulations (including the recent regulation on cross-border data transfer), how should life sciences companies navigate through and ensure compliance with these laws?</li><li>The regulatory glance has never been stricter for life sciences companies. What are the sanctions and export controls trends, and what are the potential implications of the BioSecure Act for MNCs and Chinese biotechnology companies? What are the mitigation strategies and measures companies should take?</li><li>Identifying and mitigating potential risks of patent infringement lawsuits continues to be a key topic for life sciences IP strategists.</li></ul>Find more about the <a href="https://informaconnect.com/chinabio-partnering/agenda/2/" target="_blank">event</a>.<hr>

ChinaBio® Partnering Forum 2024: Top Five Risks and Opportunities to Watch in China Life Sciences in the Coming Year

Sign Up

Chuan Sun is Managing Partner of the Shanghai and Hong Kong offices.Chuan focuses his practice on cross-border M&A transactions; sophisticated technology, media, and telecom (TMT) transactions; and complex IP/commercial matters across Greater China.With more than 20 years of experience in both Asia and the U.S., Chuan regularly advises multinational corporations, state-owned enterprises, private companies, and PE/VC firms in complex cross-border M&A transactions, joint ventures, strategic alliances, and business separation transactions.Chuan has extensive experience in complex corporate-commercial and technology transactions across the Fintech, e-commerce, and broader TMT sectors. His work covers payment technology, eKYC, credit technology, blockchain, e-platform arrangements, R&D, co-development, technology collaborations, and IP licensing. He also advises on strategic outsourcing, manufacturing, distribution, supply, and franchising arrangements across various industries.Chuan regularly counsels clients on cutting-edge technology and IP regulatory matters, including Fintech, data privacy, cybersecurity, data localization, cross-border data transfers, cloud computing, telecommunications, telematics, and third-party payment services.Prior to joining MoFo, he worked in the Hong Kong office of a Magic Circle firm and the Chicago office of another leading international firm.Chuan co-authored the Hong Kong & mainland China chapters of Getting the Deal Through – Telecoms and Media, 2014, 2015 & 2016; the Hong Kong & mainland China chapters of Getting the Deal Through: Market Intelligence – Telecoms and Media, 2015; and the Hong Kong chapter of Sourcing World 2nd Edition 2015.Chuan is fluent in Mandarin and English.“Chuan Sun has a wealth of knowledge on his clients’ existing products and services offerings and a good understanding of what terms they are or are not willing to accept. This helps tremendously with contract negotiations.”“Chuan Sun has extensive experience in the technology space. Many other competitor firms in the technology space are not really pure IT lawyers, as they are more focus on privacy and trade marks or other related fields, as opposed to technology contracts such as SAP or Microsoft software license agreements. A normal general commercial lawyer would not be able to identify the same issues or raise the right questions, as they are not equipped with the technology know-how of the products and services, their benefits, and general industry standard terms and trending patterns in the market.” Legal 500 Asia Pacific 2020<h4>Representative Experience:</h4><ul><li>CPE, a Chinese alternative investment firm, in connection with its US$350 million joint venture with Restaurant Brands International (RBI), one of the world's largest multinational fast food holding company, to operate Burger King in China which has around 1,250 restaurants in total. This transaction is one of the most significant private equity-led transactions in China’s consumer sector in 2025.</li><li>OcuMension Therapeutics (HKSE: 01477), a Hong Kong Stock Exchange listed ophthalmic pharmaceutical platform in China in its acquisition of substantial assets valued at HK$1.28 billion (approximately US$165 million) from Alcon Inc., a global leader in eye care. The transaction involves asset purchase, global license, transition services and manufacture and supply arrangement and constitutes a very substantial transaction of OcuMension.</li><li>Ascendent Capital Partners in its US$1.66 billion privatization of Hollysys Automation Technologies Ltd. (NASDAQ: HOLI), a leading international automation control system solutions provider. This is a rare transaction where a PE fund successfully acquires a US-listed Chinese company without forming a consortium with controlling shareholder or management. It is also the first and only U.S. take-private of a BVI-incorporated company involving a dissenter process. </li></ul><ul><li>Leading Global, China-Headquartered Fintech Company. Advise the company in connection with its first provision of blockchain and Real World Asset solutions in the fintech industry to a leading Chinese securities company for the latter’s first launch of structured product tokens, enabling secure, transparent, tamper-proof transactions for fixed-income and principal-protected tokenized products linked to US equity ETFs.</li><li>Leading Global, China-Headquartered Fintech Company. Advise the company in connection with the international expansion of its various business operations that are based on cutting-edge technologies, including blockchain and crypto, into multiple jurisdictions. </li></ul>

孙川是美富上海办公室和香港办公室的管理合伙人。孙川律师的执业领域集中在大中华区的跨境并购交易，复杂的技术、媒体和电信(TMT)交易以及复杂的知识产权/商务事宜。孙律师在亚洲和美国有20多年工作经验，他经常代理跨国公司、国有企业、私人企业和私募股权/风险投资机构处理复杂的跨境并购交易、合资、战略联盟和业务拆分等交易。孙律师在战略性的公司商务和技术交易方面也拥有极为丰富的经验，包括外包、制造、分销、供应与特许经营安排，以及跨行业知识产权许可安排等。他在TMT和知识产权监管方面的经验包括电信、电子商务、互联网、网络安全、数据隐私、云计算以及车联网。在加入美富前，孙律师在一家 “魔法圈”律所(Magic Circle)的香港办事处和另一家领先的国际律所的芝加哥办事处工作。孙律师与他人合著了2014，2015和2016版《让交易推进下去––电信与媒体》(Getting the Deal Through – Telecoms and Media)中的香港和中国大陆章节，2015年版《让交易推进下去：市场情报––电信与媒体》(Getting the Deal Through: Market Intelligence – Telecoms and Media)中的香港和中国大陆章节，以及2015年《采购世界》第二版(Sourcing World 2nd Edition)的香港章节。2018年《亚太法律500强》指出“孙川律师十分高效、负责和实际。他非常擅长处理IT协议，包括软件许可和IT采购合同的相关事宜。他也十分善于处理跨境TMT交易。”孙律师精通普通话和英语。<h4>具有代表性的交易 </h4><ul><li>代表中国另类投资公司CPE源峰 就其与世界上最大的餐饮公司之一餐饮品牌国际集团（Restaurant Brands International，简称 RBI）成立价值3.5亿美元的合资企业。该合资企业将负责汉堡王在中国的运营，目前在全国拥有约 1,250 家餐厅。本次交易是 2025 年中国消费行业中由私募股权基金主导的最具代表性交易之一。</li><li>代表香港上市的中国眼科制药平台欧康维视生物医药(HKSE: 01477)处理其收购全球眼科护理领域的领导者爱尔康公司价值 12.8 亿港元（约 1.65 亿美元）重大资产的事宜。交易涉及资产收购，以及全球许可、过渡期服务、生产和供应安排等，是欧康维视的一项非常重大交易。</li><li>代表上达资本处理其以16.6亿美元对和利时自动化技术有限公司（纳斯达克证券交易所股票代码：HOLI）进行私有化事宜。和利时是一家领先的国际自动化控制系统解决方案提供商。这是一宗罕见的交易。在这宗交易中，私募股权基金在未与控股股东或管理层组建财团的情况下，就成功收购了在美国上市的中国公司。这也是首宗且唯一一宗涉及异议股东程序的，在英属维尔京群岛注册成立的公司的美国上市公司私有化交易。</li><li>代表一家总部位于中国的全球领先金融科技公司首次为金融科技行业提供区块链及现实世界资产（RWA）解决方案，协助一家中国头部证券公司首次发行结构化产品代币。该方案为挂钩美国股票ETF的固定收益及保本型代币化产品提供了安全、透明且防篡改的交易支持‌。</li><li>代表一家总部位于中国的全球领先金融科技公司处理基于区块链和加密货币等尖端技术开展的各项业务在多个司法管辖区进行国际扩张的事宜。</li></ul>

Chuan Sun

Managing Partner, Shanghai and Hong Kong

Dr. Janet (Jian) Xiao is a leading patent attorney specializing in global patent procurement, patent portfolio management, and IP strategic planning for life sciences and biopharmaceutical companies. Recognized by Chambers USA and Chambers Global as a top-ranked intellectual property lawyer, Dr. Xiao is highly sought after by biotech and pharmaceutical innovators worldwide for patent prosecution, patent strategy, and life sciences IP counsel.Dr Xiao’s clients range from large renowned multinational companies to emerging startups worldwide. She advises her clients on patent matters relating to various technologies including antibody therapeutics, cell therapeutics, nanomedicine, gene therapy, drug delivery systems, diagnostics, and nutraceuticals. Recognized for her deep understanding of the industry and knowledge of IP, Janet is known for developing and strengthening her clients’ complex patent portfolios to maximize their commercial value and success. She has been instrumental on the strategy development for multibillion-dollar patent portfolios for pharmaceutical clients, and adds tremendous value by combining her creative legal skills, keen business acumen, and solid foundation in science. As impressed clients noted to Chambers, “Janet consistently delivers a very high level of client service and exhibits strong commercial awareness and vision.”Janet works extensively in performing IP due diligence reviews in the contexts of VC investments, technology transactions, mergers and acquisitions, as well as marketing and manufacturing clearance for biopharmaceutical products. She works closely with her clients to assess potential risks and devise preemptive risk-management strategies for their product development and investments. She has led hundreds of IP due diligence projects, and is most notable for her deep knowledge about patent landscapes in the fields of cancer immunotherapy, gene editing, next-generation sequencing, liquid biopsy, antibody manufacturing, and medical devices. Janet works synergistically with patent litigators in the event of legal challenges by third-party competitors or vice versa, and is frequently called upon to represent clients in litigation and post-grant proceedings.Janet is among the very few IP attorneys in the world who are both equipped with solid skills in global strategic IP management and knowledgeable about IP issues unique to China and Chinese clients, and she has been the go-to counsel for IP issues in U.S./China cross-border transactions and operations in China. As Chambers Global 2024 notes, “She is great, very strong and thoughtful. She has a very large contingent of Chinese companies.”Janet is the Head of China Life Sciences at Morrison Foerster and served as co-chair of the firm’s global Life Sciences Group from 2016 to 2019. Chambers Global states that Janet “is recognized for her knowledge of IP law relating to the life sciences arena,” and that she is “held in high regard by sources for her deep understanding of the pharmaceutical and biotech industries.” In a recent edition of Chambers Global, a client remarks, “Janet is a wonderful lawyer. She is very experienced in advising life sciences clients doing business in China and the US. She is highly responsive and always gives practical advice. Her IP expertise adds tremendous value to our business.”

肖荐（Janet Xiao）博士的业务侧重于为生命科学公司处理在全球范围内的专利采购、专利组合管理和战略策划事宜。肖博士服务的客户范围广泛，包括大型跨国生物制药公司，例如赛尔基因公司（Celgene）和基因泰克公司（Genentech），也包括全球范围的新兴创业公司。她经常就与各种技术有关的专利事宜向客户提供法律意见，其中涉及的技术包括抗体疗法、细胞疗法、纳米医学、基因疗法、给药系统、诊断和和营养学等。来自全球的创新者纷纷向肖博士寻求专利申请和专利战略的法律咨询，这一点也得到了《钱伯斯指南》的认可。她帮助客户开发和加强其复杂的专利组合，从而为客户实现最大的商业价值。在为制药行业的客户制定数十亿美元专利组合的战略方面，肖博士发挥着重要的作用。《钱伯斯指南》曾引用客户评价称，“肖博士是我曾合作过的律师当中知识最渊博、效率最高的一位律师。她能很好地将专利组合的历史信息用于全球专利申请问题上。”肖博士针对风险投资、技术交易、并购和生物医药产品的市场推广与生产许可事宜开展广泛的知识产权尽职调查审查工作。她协助世界上一些最成功的生物制药公司和投资者，为其产品开发和投资评估潜在风险，并制定先发制人的风险管理策略。她曾牵头处理过数百个知识产权尽职调查项目，并凭借自己对癌症免疫治疗、基因编辑、新一代测序、液体活检、抗体制造和医疗设备领域的专利方面的深厚知识而闻名。肖博士时常与专利诉讼律师合作，处理由第三方竞争者提出的法律质疑，或对第三方竞争者提出的法律质疑，她还经常受聘代表客户处理专利诉讼和授予后程序。肖博士是美富中国生命科学业务组主管，她曾在2016至2019期间担任美富全球生命科学业务组的联席主管。肖博士是全球为数不多的既拥有很强的全球战略性知识产权管理技能，同时又对中国和中国客户独特的知识产权问题具有深刻理解的知识产权律师之一，她一直是处理中美跨境交易和在中国境内经营中所涉知识产权问题的首选律师。《钱伯斯全球指南》称赞她是一位优秀的知识产权律师，“她因处理与复杂跨境交易有关的知识产权问题工作而知名，经常代表中国客户处理这方面的事宜” 。在近期一版《钱伯斯全球指南》中，某客户评价称，“肖博士在为于中国和美国开展业务的生命科学客户提供法律意见方面，有非常丰富的经验。她非常负责而且总是提供切实可行的法律意见。她在知识产权方面的专业意见为我们的业务增添了巨大价值。”自2005年以来，肖博士一直积极参与北美华人生物医药协会（CABS）的领导工作。该协会是一家非营利组织，致力于成为连接中美两国生命科学领域的纽带。肖博士在2011至2012年间担任该协会主席。她还是百华协会（BayHelix）的成员。百华协会是一家非营利组织，由全球生命科技和医疗保健产业领域的华人精英组成。

Janet Xiao

Partner

Chen is the head of Morrison Foerster’s Sanctions and Export Controls practice for Asia and leads the firm’s government and internal investigations in Greater China. Chen has extensive experience advising on U.S. economic sanctions, anti-corruption, anti-money laundering, securities and accounting fraud, and related governance and corporate compliance issues.Chen frequently advises Chinese, U.S., and European financial institutions on U.S. economic sanctions and export controls in the context of contentious enforcement matters involving OFAC and other U.S. regulators. He also frequently assists banks and corporates with setting up practical, risk-based sanctions and export controls compliance programs.In addition, Chen has been lead counsel on  numerous anti-corruption enforcement actions by U.S. regulators against some of the largest major life sciences, technology, and financial services companies over the past eighteen years. He regularly counsels company boards and senior management on corporate investigations and compliance remediation.His clients include major state-owned enterprises, multinational corporations, and executives from financial services, life sciences, technology, consumer retail, and hospitality sectors, with a particular focus on Greater China, Japan, South Korea, and Southeast Asia.Chen has been ranked as a leading investigations lawyer in Corporate Investigations/Anti-Corruption (International Firms) by Chambers Greater China 2024-2026, Lexology Index Investigations 2024 – 2025 and Who’s Who Legal Investigations 2019-2023. He is also recommended in China/Hong Kong for regulatory/compliance and dispute resolution: litigation by Legal 500 2022 – 2026 and for life sciences and healthcare by Legal 500 2024 – 2025.Chen is a frequent presenter at legal conferences and client workshops relating to anti-corruption, economic sanctions, and white-collar enforcement.Prior to joining Morrison Foerster, he worked in the Hong Kong and New York offices of a leading U.S. law firm.Chen is a native speaker of English and Mandarin. He is a Registered Foreign Lawyer with the Law Society of Hong Kong.

朱晨昊律师是美富亚洲制裁与出口管制业务组的负责人，同时领导本所在大中华区的政府和内部调查工作。朱律师在处理美国经济制裁、反腐败、反洗钱、证券与会计欺诈，以及相关的企业治理和公司合规事宜方面经验十分丰富。朱律师经常在涉及外国资产控制办公室（OFAC）和其他美国监管机构的具争议性执法事务中，为中国、美国和欧洲金融机构就美国经济制裁和出口管制事宜提供法律意见。他还经常协助银行和公司制定切实可行、基于风险的制裁和出口管制合规计划。在过去18年里，朱律师曾担任主理律师处理过众多由美国监管机构发起的，针对一些最大型生命科学、技术和金融服务公司的美国反腐败执法行动。他经常就公司调查和合规补救问题为公司董事会和高级管理层提供法律咨询服务。朱律师的客户包括金融服务、生命科学、技术、消费品零售以及酒店业等多个行业的大型国有企业、跨国公司和高级管理层，其业务重点是大中华区、日本、韩国和东南亚地区。朱律师广获知名法律排名机构认可，曾被评为2024—2026年《钱伯斯大中华区法律指南》 企业调查/反腐败（国际所）、2024—2025年Lexology Index Investigations和2019—2023年《法律名人录之调查业务》领先律师、2022—2026年《法律500强》中国大陆/香港地区监管/合规和争议解决类诉讼业务推荐律师，以及2024—2025年《法律500强》中国大陆/香港地区生命科学和医疗保健业务推荐律师。朱律师经常在与反腐败、经济制裁和白领执法相关的法律会议和客户研讨会上发表演讲。在加入美富之前，朱律师在一家顶级美国律所的香港和纽约办事处任职。朱律师的母语是英文和普通话。他是香港律师会的注册外国律师。

B. Chen Zhu

Sarah frequently advises clients in strategic corporate-commercial and technology transactions in the sectors of life science and TMT, including in-licensing, out-licensing, collaboration, and development agreements in various types of traditional and emerging technology offerings, including software-as-a-service, on-premises software, and technology services and maintenance, and in a broad range of pharmaceutical products and technologies, including biopharmaceutical drugs, immunotherapies, antibody therapeutics, and vaccines.Before joining MoFo, Sarah was an associate in the Shanghai office of an international law firm. She is fluent in English and Mandarin.<h4>Representative Experience</h4><ul><li>A leading healthcare investment firm’s portfolio company in its series of license-in and license-out deals concerning: (i) the development and option agreement and license agreement with a private biotechnological company in the North America for the development of lipid nanoparticles (LNP) formulations for delivery of mRNA and for the commercialization and manufacturing of the protein product and the vaccine product utilizing the LNP technology; and (ii) the licensing-out agreement with a Hong Kong listed company for the development and commercialization of the mRNA technology in Greater China.</li></ul><ul><li>Hangzhou DAC Biotechnology Co., Ltd. on its collaboration and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the development and commercialization of antibody drug conjugate (ADC) products.</li><li>Jiangsu Hengrui Medicine Co., Ltd. in its US$165 million exclusive license agreement with Novaliq GmbH, a German pharmaceutical company focusing on ocular therapeutics, to develop, manufacture and commercialize the innovative, water-free drugs NOV03 (perfluorohexyloctane) and CyclASol® for the treatment of dry eye disease in mainland China, Hong Kong, Macau and Taiwan.</li><li>A FinTech firm in the strategic partnership between a pan-Asia retailer and a Hong Kong bank to construct a new customer loyalty and reward program to replace the current co-branded credit card program on the market.</li><li>An automobile retailer that is a subsidiary of a multi-national dealership operator in its ERP software license and support agreement and the service agreement with a European multi-national software corporation, on the subscription of its core software products and technologies.</li></ul>

王家尧律师经常就生命科学以及科技、媒体和电信（TMT）领域战略性的公司商业交易和技术交易向客户提供咨询，包括协助客户编制被许可协议、对外许可协议、协作协议及开发协议，涉及各种传统及新兴技术产品和服务，包括软件即服务（SaaS）、本地部署软件以及技术服务和维护等，还涉及广泛的医药产品和技术，包括生物制药产品、免疫疗法、抗体疗法和疫苗等。在加入美富前，王律师是一家国际律所上海办事处的律师。她精通英语和普通话。<h4>具有代表性的项目 </h4><ul><li>代表某顶级医疗保健投资机构的被投资公司处理涉及下列事宜的系列被许可及对外许可交易：（1）代表某领先的生物医药公司就其与加拿大某生物公司签订开发和选择权协议以及对内许可协议提供法律服务，以开发用于传递mRNA的脂质纳米颗粒（LNP）配方，并对利用LNP技术的蛋白质产品和疫苗产品进行商业化和生产；以及（2）与某香港上市公司签订对外许可协议，以在大中华区对mRNA技术进行开发和商业化。</li></ul><ul><li>代表杭州多禧生物科技有限公司与强生公司旗下杨森制药生物科技公司达成合作和许可协议，用于抗体偶联药物（ADC药物）的开发与商业化。</li></ul><ul><li> 代表江苏恒瑞医药股份有限公司处理其与Novaliq GmbH（一家专注于眼部治疗的德国制药公司）的1.65亿美元独家许可协议，对创新型无水药物NOV03（全氟己内酯）和CyclASol®进行开发、生产和商业化，用于在中国大陆、香港、澳门和台湾地区治疗干眼症。</li></ul><ul><li> 代表一家金融科技公司处理其所属的泛亚洲零售商与一家香港银行的策略性合伙，订立新的老顾客奖励计划来取代目前市场上的联合品牌信用卡计划。</li></ul><ul><li> 代表一家国际汽车经销集团旗下的汽车零售商，处理其ERP软件许可证和支持协议及与一家欧洲国际软件公司的服务协议，以订阅模式付费使用其核心软件产品和技术。</li></ul>

ChinaBio® Partnering Forum 2024: Top Five Risks and Opportunities to Watch in China Life Sciences in the Coming Year

10 Sep 2024 1:30 PM - 2:30 PM HKT